Development
Alto Neuroscience, Inc.
ANRO
$2.57
$0.197.98%
NYSE
| 12/31/2022 | |||||
|---|---|---|---|---|---|
| Net Income | -7.65M | ||||
| Total Depreciation and Amortization | 97.00K | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | 716.00K | ||||
| Change in Net Operating Assets | 818.00K | ||||
| Cash from Operations | -6.02M | ||||
| Capital Expenditure | -62.00K | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -62.00K | ||||
| Total Debt Issued | 9.83M | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | 4.00K | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | 10.04M | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -157.00K | ||||
| Cash from Financing | 19.71M | ||||
| Foreign Exchange rate Adjustments | 20.00K | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | 13.65M | ||||